TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses. Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD (at) tiltbio.com
View Top Employees from TILT Biotherapeutics LtdWebsite | http://tiltbio.com/ |
Revenue | $3 million |
Funding | $11.3 million |
Employees | 23 (21 on RocketReach) |
Founded | 2013 |
Address | Biomedicum 2b 8 b Tukholmankatu Fl 2, Helsinki 00290, FI |
Phone | +358 9 19125464 |
Technologies |
HTML,
Twitter,
jQuery
+3 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Apps, Oncolytic Viruses, Business Services, Software, Solid Tumors, Biotechnology, Enabling T-Cell Therapy (Tils, Car-T, Checkpoint Inhibitors), Science and Engineering, Cancer, Health Care |
Competitors | Adaptive Biotechnologies Corp., Gilead Sciences, Juno Therapeutics, Inc., Takeda China, iRepertoire, Inc. |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541713 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies |
Looking for a particular TILT Biotherapeutics Ltd employee's phone or email?
The TILT Biotherapeutics Ltd annual revenue was $3 million in 2024.
Akseli Hemminki is the CEO of TILT Biotherapeutics Ltd.
21 people are employed at TILT Biotherapeutics Ltd.
The NAICS codes for TILT Biotherapeutics Ltd are [54171, 541713, 54, 5417, 541].
The SIC codes for TILT Biotherapeutics Ltd are [873, 87].